Unknown PHASE3 INTERVENTIONAL NCT00149084

Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori

Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori

Sponsor: Hamamatsu University

Conditions Duodenal Ulcer Gastric Ulcer Gastritis Helicobacter Infections

Interventions Lansoprazole, clarithromycin, amoxicillin

Updated 5 times since 2017 Last updated: Sep 8, 2006 Started: Apr 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00149084, this PHASE3 trial focuses on Duodenal Ulcer and Gastric Ulcer and remains ongoing. Sponsored by Hamamatsu University, it has been updated 5 times since 2003, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hamamatsu University
Yokoyama Foundation for Clinical Pharmacology

Data source: Hamamatsu University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hamamatsu, Japan